AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Israel orders $183 million in air-to-ground bombs from Elbit
2
Intel employees receive 1.8-month bonus in rebound from last year’s cut
3
“SaaS is dying as a business category”
4
Factify raises $63 million in Seed funding to kill the PDF and build a new document standard for AI
5
“We built monday in four hours using our system”
More news

Cancer

11 stories about Cancer
default image

Pharma Company BioCanCell Raises $25 million, Plans to Go Public in the U.S.

23.01.18|Asaf Shalev
The company said it will use the funding for clinical trials of BC-819, a drug being designed to treat early stage bladder cancer
פרופסור זליג אשחר

Scientist’s Ex-Wife Joins Legal Melee Over Kite Pharma Windfall

16.01.18|Zohar Shahar Levy
Zelig Eshhar, the patent holder for Kite Pharma’s anti-cancer technology, is currently being sued by a former student for infringement of patent rights
פרופסור זליג אשחר

Immunologists Exchange Verbal Blows in Legal Fight Over Kite Pharma Windfall

26.12.17|Zohar Shahar Levy
In August, Gilead Science bought anti-cancer treatment company Kite Pharma for $11.9 billion. Two Israeli scientists involved in the early research that led to the company’s breakthrough are now quarreling over patent royalty payments
מייסד קייט פארמה אריה בלדגרין

Gilead Builds on Kite Pharma Acquisition, Buys Second CAR-T Therapy Company

10.12.17|Lilach Baumer
California-based Cell Design Labs will be acquired in a deal valued at up to $567 million
המדען הראשי ב כלל ביוטכנולוגיה ד"ר ג'וליאן אדמס

Pharma Veteran Julian Adams takes Helm at Gamida Cell

21.11.17|Lilach Baumer
The Novartis-backed company is developing a universal bone marrow transplant solution for patients unable to find a donor
דרור חרץ מנכ"ל VBL

VBL Therapeutics Aims to Raise $18.75 Million in Public Offering

20.11.17|Lilach Baumer
The cancer treatment company announced an offering of 2.5 million shares last week
default image

Pontifax Leads $9.5 Funding Round for Biopharmaceutical Company ArQule

19.11.17|CTech
Nasdaq-listed ArQule develops treatments for cancer and rare diseases
default image

Generic Focus made Kite Pharma Founder Leave Teva

13.11.17|Dror Reich
Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"
default image

Cancer Treatment Company Negotiating $20-25 Million Capital Injection

29.10.17|Lilach Baumer
The potential investors condition the investment on delisting BioCanCell from the Tel Aviv Stock Exchange
default image

Kite Pharma’s Cancer Drug Gets Regulatory Nod

19.10.17|Lilach Baumer
The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000
מוסף שבועי 14.9.17 פרופ' גידי גרוס

Kite Pharma Sale Triggers Scientist Quarrel

02.10.17|Zohar Shahar Levy
Zelig Eshhar who patented the company’s core technology is now being sued by his former PhD student and current pharma entrepreneur
Previous Articles